Inflammation  >>  Artlegia (olokizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Artlegia (olokizumab) / R-Pharm
RESET, NCT05187793: Study of Efficacy of Different Treatment Regimens of Olokizumab

Active, not recruiting
3
198
RoW
Olokizumab, Standard therapy
R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС
COVID-19
10/22
04/23

Download Options